Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  talazoparib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-14 of 14 for your search:
Start Over
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 673-301, U1111-1155-7579, NCT01945775
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140015, 14-C-0015, NCT01989546
BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-00804, ADVL1411, UM1CA097452, NCT02116777
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 673-201, NCT02034916
A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/13/0045, 2013-003469-32, NCT02127151
Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0045, NCI-2015-00335, NCT02282345
Phase II Study of BMN 673
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0961, NCI-2014-02494, NCT02286687
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 150050, 15-C-0050, NCT02326844
PARP Inhibitor BMN-673 in Treating Patients With BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRS0050, NCI-2015-00036, P30CA124435, NCT02401347
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: TRIO-US GI-07, NCI-2014-00048, P30CA016042, NCT02049593
PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-02474, NCI 9782, 9782, P30CA072720, UM1CA186716, NCT02317874
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14955, NCT02358200
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: BMNIRN, NCI-2015-00255, NCT02392793
POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0474, NCI-2014-02608, NCT02316834
Start Over